MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.
Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker NAM, van den Broek D, Pronk LM, Grijpink-Ongering LG, Sari A, Kessels R, van den Haak M, Mallo HA, Karger M, van de Wiel BA, Zuur CL, Duinkerken CW, Lalezari F, van Thienen JV, Wilgenhof S, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG.
Rohaan MW, et al.
Immunooncol Technol. 2022 Jun 18;15:100089. doi: 10.1016/j.iotech.2022.100089. eCollection 2022 Sep.
Immunooncol Technol. 2022.
PMID: 35865122
Free PMC article.
We investigated the safety and feasibility of adoptive transfer of autologous T cells expressing melanoma antigen recognized by T cells 1 (MART-1)-specific TCR, cultured to have less differentiated phenotypes, in patients with metastatic melanoma. MATERIALS AND METHODS: In …
We investigated the safety and feasibility of adoptive transfer of autologous T cells expressing melanoma antigen recognized by T cells 1 ( …